KaliVir Immunotherapeutics
1 known investors
Find your way into KaliVir Immunotherapeutics
1,430 people in our graph share verified history with the KaliVir Immunotherapeutics team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows Stephen Thorne · together at Stanford University (overlapped)
×7knows the team · via Morgan Stanley
knows the team · via University of Oxford
×2knows the team · via Cancerresearchuk
knows the team · via Bank of America
KaliVir develops oncolytic virus immunotherapies for cancer treatment based on its Vaccinia Enhanced Template (VET) backbone, which uses proprietary genetic modifications to a vaccinia virus optimized for intravenous systemic delivery and expression of therapeutic transgenes within tumors. The technology targets tumor replication and metastatic spread while modulating anti-tumoral immunity.
Founders & leadership
ST
Stephen ThorneinCo-founder & Chief Scientific OfficerStephen Thorne is Co-founder and Chief Scientific Officer of KaliVir Immunotherapeutics, an immuno-oncology company developing oncolytic viral immunotherapies for solid tumors. He brings over 15 years of research and leadership experience in translational development of cancer immunotherapies, including immune cell therapies, oncolytic viral therapies, and gene therapy, along with expertise in immunocompetent mouse models, molecular imaging, and process development for complex biologics.
SG
Schond GreenwayinChief Financial OfficerSchond Greenway is Chief Financial Officer of KaliVir Immunotherapeutics, bringing over 25 years of finance experience across investment banking, equity research, and capital markets roles at publicly traded life sciences companies, where he secured substantial growth capital for early-stage firms.
JB
James BurkeinChief Medical Officer
Investors · 1
Funding
SEC filings, press & company announcements$14M disclosed across 1 of 2 rounds · 2026
Source: company announcements and press reports — follow each round's link for the claim.
In the news
KaliVir raises USD 14m as oncolytic virus clears first IV cohortallsci.com · Aug 2026
KaliVir Immunotherapeutics Announces Closing of $14 Million Series A Extension Financing - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does KaliVir Immunotherapeutics do?
- KaliVir develops oncolytic virus immunotherapies for cancer treatment based on its Vaccinia Enhanced Template (VET) backbone, which uses proprietary genetic modifications to a vaccinia virus optimized for intravenous systemic delivery and expression of therapeutic transgenes within tumors. The technology targets tumor replication and metastatic spread while modulating anti-tumoral immunity.
- Who founded KaliVir Immunotherapeutics?
- KaliVir Immunotherapeutics was founded by Stephen Thorne.
- Who are KaliVir Immunotherapeutics's investors?
- KaliVir Immunotherapeutics's investors include Premier Partners.
- How much funding has KaliVir Immunotherapeutics raised?
- KaliVir Immunotherapeutics has disclosed $14M raised across 1 of its 2 known rounds.